TY - JOUR
T1 - Bone loss or lost bone
T2 - Rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss
AU - Zaidi, Mone
AU - Turner, Charles H.
AU - Canalis, Ernesto
AU - Pacifici, Roberto
AU - Sun, Li
AU - Iqbal, Jameel
AU - Guo, X. Edward
AU - Silverman, Stuart
AU - Epstein, Solomon
AU - Rosen, Clifford J.
N1 - Funding Information:
The authors are grateful to Ms. Mary Jo Sweeney for expert editorial assistance. Dr. Mone Zaidi, Dr. Charles Turner, Dr. Roberto Pacifici, Dr. Ernesto Canalis, Dr. Li Sun, Dr. X. Edward Guo, and Dr. Clifford Rosen all acknowledge the National Institutes of Health for supporting research in their respective laboratories. Dr. Jameel Iqbal acknowledges support from the American Federation for Aging Research.
PY - 2009/12
Y1 - 2009/12
N2 - Recent reports suggest that bone loss begins during late perimenopause at a dramatic rate, even before estrogen levels plummet. During the ensuing 5 years, there is evidence of the beginnings of microarchitectural deterioration, which impacts bone strength and ultimately enhances its propensity to fracture. The diagnosis of osteoporosis based on T-scores alone, or through stratification for a high fracture risk by FRAX, excludes these women who are rapidly losing bone. Because all antiosteoporosis therapies, in particular bisphosphonates, reduce bone loss, we propose aggressive, likely short-term therapy with a goal to reduce bone loss, stabilize bone density, and prevent microarchitectural deterioration.
AB - Recent reports suggest that bone loss begins during late perimenopause at a dramatic rate, even before estrogen levels plummet. During the ensuing 5 years, there is evidence of the beginnings of microarchitectural deterioration, which impacts bone strength and ultimately enhances its propensity to fracture. The diagnosis of osteoporosis based on T-scores alone, or through stratification for a high fracture risk by FRAX, excludes these women who are rapidly losing bone. Because all antiosteoporosis therapies, in particular bisphosphonates, reduce bone loss, we propose aggressive, likely short-term therapy with a goal to reduce bone loss, stabilize bone density, and prevent microarchitectural deterioration.
UR - https://www.scopus.com/pages/publications/72849125316
U2 - 10.1007/s11914-009-0021-4
DO - 10.1007/s11914-009-0021-4
M3 - Review article
C2 - 19968915
AN - SCOPUS:72849125316
SN - 1544-1873
VL - 7
SP - 118
EP - 126
JO - Current Osteoporosis Reports
JF - Current Osteoporosis Reports
IS - 4
ER -